Momenta Pharmaceuticals, Inc.  

(Public, NASDAQ:MNTA)   Watch this stock  
Find more results for MNTA
-0.07 (-0.59%)
After Hours: 11.80 0.00 (0.00%)
Oct 25, 4:19PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 11.77 - 12.07
52 week 7.86 - 18.85
Open 11.90
Vol / Avg. 291,921.00/470,353.00
Mkt cap 829.92M
P/E     -
Div/yield     -
EPS -1.53
Shares 70.98M
Beta 1.75
Inst. own 84%
Nov 2, 2016
Q3 2016 Momenta Pharmaceuticals Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Sep 7, 2016
Momenta Pharmaceuticals Inc at Wells Fargo Securities Healthcare Conference - Webcast
Aug 4, 2016
Q2 2016 Momenta Pharmaceuticals Inc Earnings Call
Aug 4, 2016
Q2 2016 Momenta Pharmaceuticals Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '16) 2015
Net profit margin -79.40% -92.93%
Operating margin -81.87% -94.18%
EBITD margin - -84.14%
Return on average assets -19.55% -24.60%
Return on average equity -24.54% -28.91%
Employees 258 -
CDP Score - -


675 W Kendall St
CAMBRIDGE, MA 02142-1110
United States - Map
+1-617-4919700 (Phone)
+1-617-6210431 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Momenta Pharmaceuticals, Inc. is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. It focuses on three product areas: Complex Generics, Biosimilars and Novel Therapeutics. It has developed generic version of Lovenox (enoxaparin sodium injection). Its GLATOPA is a generic version of once-daily COPAXONE 20 milligrams/milliliter (mg/mL) indicated for the treatment of patients with relapsing-remitting multiple sclerosis (RRMS), a chronic disease of the central nervous system characterized by inflammation and neurodegeneration. It is developing M923, which is a biosimilar of HUMIRA and M834 as a biosimilar of ORENCIA. Its oncology product candidate Necuparanib, is an oncology product candidate, which have a range of effects on tumor cells and the environment, in which tumor cells grow. It focuses on M281, which is an Anti-FcRn program.

Officers and directors

James R. Sulat Independent Chairman of the Board
Age: 66
Bio & Compensation  - Reuters
Craig A. Wheeler President, Chief Executive Officer, Director
Age: 55
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Ganesh Venkataraman Kaundinya Ph.D. Co-Founder, Senior Vice President - Research, Chief Scientific Officer
Age: 49
Bio & Compensation  - Reuters
Richard P. Shea Chief Financial Officer, Senior Vice President
Age: 64
Bio & Compensation  - Reuters
Matthew P. Ottmer Chief Operating Officer
Age: 45
Bio & Compensation  - Reuters
Bruce A. Leicher Senior Vice President, General Counsel, Secretary
Age: 60
Bio & Compensation  - Reuters
Jo-Ann Beltramello Senior Vice President - Human Resources
Bio & Compensation  - Reuters
James Anderson Ph.D. Senior Vice President - Pharmaceutical Sciences
Bio & Compensation  - Reuters
Ian D. Fier Senior Vice President - Program and Project Management
Age: 43
Bio & Compensation  - Reuters
Young Kwon Ph.D. Senior Vice President - Corporate Development and Strategy
Bio & Compensation  - Reuters